1,641 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,641 shares of the medical research company's stock, valued at approximately $539,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Metis Global Partners LLC boosted its stake in Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock valued at $234,000 after acquiring an additional 30 shares during the last quarter. Signaturefd LLC grew its stake in Bio-Rad Laboratories by 13.2% in the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after purchasing an additional 31 shares in the last quarter. UMB Bank n.a. increased its holdings in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in Bio-Rad Laboratories by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after buying an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in Bio-Rad Laboratories by 3.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after buying an additional 34 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

NYSE BIO traded down $7.52 during trading hours on Friday, hitting $242.22. The company had a trading volume of 377,689 shares, compared to its average volume of 317,205. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99. The firm has a market cap of $6.78 billion, a P/E ratio of -3.72 and a beta of 1.12. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $251.03 and a 200-day simple moving average of $308.11.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BIO. Royal Bank of Canada reissued an "outperform" rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Wells Fargo & Company reduced their price target on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Bio-Rad Laboratories has an average rating of "Moderate Buy" and an average price target of $380.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.